[DBV] Powershares DB G10 Currency Harvest Fund

Overview

Type of security: Fund

Tags: 2X, Broad currency, Carry trade, Currency, Developed markets, ETF, G10, Index Based, Leveraged, Long-Short, Market Neutral, Not Inversed, Regional

The data is delayed by 15 minutes.

 

Price: 24.92 Change: -0.05 (-0.2%)
Ext. hours: Change: 0 (0%)

chart DBV

Refresh chart

Strongest Trends Summary For DBV

DBV is in the medium-term down -3% in 1 month.

Horizon: 3 hours | 2 days | 5 days | 10 days | 1 month | 6 months | 1 year | 2 years | 5 years | max

Chart type: absolute | relative to S&P

Publish chart

 

Description: The investment seeks to track changes, whether positive or negative, in the level of the Deutsche Bank G10 Currency Future Harvest Index®â??Excess Return. The index is comprised of long futures positions in the three Eligible Index Currencies associated with the highest interest rates and short futures positions in the three Eligible Index Currencies associated with the lowest interest rates. The indexâ??s six component currencies from time-to-time, comprised of the three long and three short futures positions, are referred to as the Index Currencies and are used to calculate the value of the index.

Technical Data
High 52 week24.99 Low 52 week23.65 Last close23.93 Last change-0.25%
RSI17.53 Average true range0.12 Beta0.41 Volume7.29 K
Simple moving average 20 days-1.87% Simple moving average 50 days-1.55% Simple moving average 200 days-1.57%
Performance Data
Performance Week-1.16% Performance Month-2.33% Performance Quart-1.89% Performance Half-0.92%
Performance Year-0.5% Performance Year-to-date-3.31% Volatility daily0.32% Volatility weekly0.71%
Volatility monthly1.46% Volatility yearly5.07% Relative Volume40.8% Average Volume1.17 K
New High New Low
Funds Characteristics
30-day SEC yield Average market capitalization Average weighted market capitalization Forward P/E
Gross expense ratio Index dividend yield Median market cap Number of holdings
Price to Book Value Price to Earnings Total expense ratio0.81% Total net assets
Weighted market capitalization

Info

Characteristics:
NAME VALUE
Total Expense Ratio0,81
Currencies:
NAME VALUE
Australian Dollar
Canadian Dollar
New Zealand Dollar
U.s. Dollar
British Pounds
Japanese Yen
Euro
Swiss Franc
Norwegian Krone
Swedish Krona

News

2019-02-04 16:01:37 | DBV Technologies to Present Data on Epicutaneous Immunotherapy at AAAAI 2019

2019-02-01 01:31:51 | DBV Technologies to Present at the 8th Annual Leerink Partners Global Healthcare Conference

2019-01-03 01:31:50 | DBV Technologies Expands and Strengthens Leadership Team

2018-12-19 17:01:36 | DBV Technologies: DBV Technologies Provides Update on Viaskin Peanut for Children Four to 11 Years of Age

2018-12-12 01:31:36 | DBV Technologies Highlights Data Supporting Induction of Immunotolerance Through the Skin at Inflammatory Skin Disease Summit 2018

2018-11-16 01:31:37 | DBV Technologies Appoints Daniel Tassé as Chief Executive Officer

2018-10-30 02:31:35 | DBV Technologies Reports September 30, 2018 Cash Position

2018-10-26 01:31:53 | DBV Technologies Announces Initiation of Part B of Phase III Study in Peanut-Allergic Toddlers

2018-09-25 01:31:52 | DBV Technologies to Present at the Cantor Global Healthcare Conference

2018-09-07 01:31:43 | DBV Technologies : Reports First Half 2018 Financial Results

2018-09-05 01:31:34 | DBV Technologies, Geneva University Hospitals and BioNet-Asia Presented Additional Phase I Data on the Use of an Investigational Epicutaneous Patch in Boosting Pertussis Vaccination at the ECI

2018-08-31 01:31:52 | DBV Technologies to Attend Upcoming Investor Conferences

2018-07-27 01:31:24 | DBV Technologies Reports June 30, 2018 Cash Position

2018-07-26 01:31:28 | DBV Technologies Appoints Industry Leader Kevin Trapp as Chief Commercial Officer

2018-06-01 01:31:46 | DBV Technologies: Ordinary and Extraordinary General Meeting of June 22, 2018 - Procedures for Obtaining Preparatory Documents for the General Meeting

2018-05-16 01:31:37 | DBV Technologies Announces Appointment of Michel de Rosen to its Board of Directors

2018-05-08 01:31:34 | DBV Technologies to Present New Clinical Data from Viaskin Platform at the 2018 EAACI Meeting

2018-04-27 01:31:41 | DBV Technologies Reports March 31, 2018 Cash Position

2018-03-26 16:02:05 | DBV Technologies Announces Closing of Underwriters' Option to Purchase Additional Shares in Global Offering

2018-03-21 03:01:47 | DBV Technologies Announces Pricing of $150.0 million €122.5 million Global Offering of Ordinary Shares, Including in the Form of American Depositary Shares

2018-03-16 16:31:33 | DBV Technologies Announces Filing of 2017 _Document de Référence_ and 2017 Annual Report on Form 20-F

2018-03-14 02:31:36 | DBV Technologies Reports Full Year 2017 Financial Results

2018-02-26 17:06:43 | DBV Technologies Announces Results from Phase II Study of Viaskin Milk in Milk-Allergic Patients

2018-02-20 01:31:59 | DBV Technologies Reports December 31, 2017 Cash Position

2018-02-14 01:31:41 | DBV Technologies Provides Update on Regulatory Progress for Viaskin Peanut

2018-02-12 09:01:49 | DBV Technologies présente de nouveaux résultats lors du Congrès Annuel 2018 de l'AAAAI/WAO concernant sa plateforme Viaskin

2018-01-16 01:31:12 | Half-Year Report on DBV Technologies Liquidity Contract with Natixis

2017-12-04 01:31:42 | DBV Technologies CEO, Chairman, and Co-Founder, Dr. Pierre-Henri Benhamou Recognized for His Lasting Impact on the Food Allergy Community and Research Advancement by FARE Food Allergy Research & E...

2017-11-14 11:31:43 | DBV Technologies Announces Publication of Positive Data from Phase IIb Trial and Long-Term Study of Viaskin Peanut in the Journal of the American Medical Association

2017-10-31 02:32:08 | DBV Technologies Reports September 30, 2017 Cash Position

2017-10-20 17:17:04 | DBV Technologies Announces Topline Results of Phase III Clinical Trial in Peanut-Allergic Patients Four to 11 Years of Age

2017-07-31 04:51:00 | US Dollar Bearishness Is Overdone

2017-06-15 16:31:53 | DBV Technologies Announces Appointment of Julie O'Neill to Board of Directors

2017-06-15 16:31:53 | DBV Technologies Announces Results of its 2017 Ordinary and Extraordinary General Meeting

2017-06-01 01:31:51 | DBV Technologies to Attend Upcoming Investor Conferences

2017-05-22 21:33:45 | Currencies Quiet After Trump’s Good Weekend

2017-05-02 01:53:20 | DBV Technologies to Attend Upcoming Investor Conferences

2017-04-28 01:49:57 | DBV Technologies Reports March 31, 2017 Cash Position

2017-03-10 01:31:25 | DBV Technologies Announces Completion of Enrollment of the REALISE Study in Peanut Allergic Children

2017-03-01 06:22:40 | POWERSHARES DB G10 CURRENCY HARVEST FUND Files SEC form 10-K, Annual Report

2017-03-01 01:31:36 | DBV Technologies to Attend Upcoming Investor Conferences

2017-02-03 01:31:56 | DBV Technologies Announces Completion of Enrollment of Phase IIA Study of Viaskin Milk for the Treatment of Pediatric Eosinophilic Esophagitis

2017-01-26 01:51:04 | DBV Technologies to Present at the LEERINK Partners 6th Annual Global Healthcare Conference

2017-01-09 01:40:15 | DBV Technologies Announces Financial Calendar 2017

2016-11-28 14:26:02 | POWERSHARES DB G10 CURRENCY HARVEST FUND Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial St

2016-11-08 15:53:22 | POWERSHARES DB G10 CURRENCY HARVEST FUND Files SEC form 10-Q, Quarterly Report

2016-10-25 17:12:39 | POWERSHARES DB G10 CURRENCY HARVEST FUND Files SEC form 8-K, Termination of a Material Definitive Agreement

2016-08-19 13:04:30 | POWERSHARES DB G10 CURRENCY HARVEST FUND Financials

2016-08-09 16:31:44 | POWERSHARES DB G10 CURRENCY HARVEST FUND Files SEC form 10-Q, Quarterly Report

2016-08-03 02:05:29 | DBV Technologies SA :DBV-FR: Earnings Analysis: For the six months ended December 31, 2015 : August 3, 2016